Wang Huan, Wang Zhao, Cao Wen, Wu Qianqian, Yuan Yujia, Zhang Xiangjian
1Department of Neurology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
2Hebei Collaborative Innovation Center for Cardio-cerebrovascular Disease, Shijiazhuang, Hebei 050000, China.
Aging Dis. 2021 Oct 1;12(7):1545-1553. doi: 10.14336/AD.2021.0709. eCollection 2021 Oct.
The outbreak of coronavirus disease 2019 (COVID-19) is caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which leads to the disruption of immune system, exacerbated inflammation, and even multiple organ dysfunction syndrome. Regulatory T cells (Tregs) are an important subpopulation of T cells that exert immunosuppressive effects. Recent studies have demonstrated that the number of Tregs is significantly reduced in COVID-19 patients, and this reduction may affect COVID-19 patients on several aspects, such as weakening the effect of inflammatory inhibition, causing an imbalance in Treg/Th17 ratio, and increasing the risk of respiratory failure. Treg-targeted therapy may alleviate the symptoms and retard disease progression in COVID-19 patients. This study highlights the recent findings on the involvement of Tregs in the regulation of immune responses to COVID-19, and we hope to provide novel perspectives on the alternative immunotherapeutic strategies for this disease that is currently prevalent worldwide.
2019年冠状病毒病(COVID-19)的爆发是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染引起的,这会导致免疫系统紊乱、炎症加剧,甚至引发多器官功能障碍综合征。调节性T细胞(Tregs)是发挥免疫抑制作用的重要T细胞亚群。最近的研究表明,COVID-19患者体内的Tregs数量显著减少,这种减少可能在多个方面影响COVID-19患者,如削弱炎症抑制作用、导致Treg/Th17比例失衡以及增加呼吸衰竭风险。针对Tregs的治疗可能会缓解COVID-19患者的症状并延缓疾病进展。本研究重点介绍了Tregs参与调节对COVID-19免疫反应的最新研究结果,希望能为这种目前在全球流行的疾病提供替代免疫治疗策略的新视角。